Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease
Launched by ERLING BJERREGAARD PEDERSEN · Jun 2, 2010
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Kidney disease corresponding to eGFR: 15-59 ml/min
- • Albuminuria \> 30 mg/l
- Exclusion Criteria:
- • Total parathyroidectomy
- • Diabetes Mellitus
- • Cancer
- • Illicit drug or alcohol abuse
- • Pregnancy og nursing
- • Ongoing NSAID or corticosteroid treatment
- • b-hemoglobin \< 6 mmol/l
- • p-albumin \< 25 mmol/l
- • Clinically significant hypercalcemia
- • Office blood pressure \> 170/105 mmHg that despite antihypertensive treatment still is \> 170/105 mmHg when using home blood pressure measurements or 24-hour ambulatory blood pressure measurement.
About Erling Bjerregaard Pedersen
Erling Bjerregaard Pedersen is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in orchestrating and managing clinical studies, he focuses on innovative therapeutic solutions across various therapeutic areas. His approach emphasizes rigorous compliance with regulatory standards, fostering collaboration among stakeholders, and ensuring the highest ethical standards in research practices. By prioritizing patient safety and data integrity, Erling Bjerregaard Pedersen aims to contribute significantly to the development of effective treatments and the advancement of clinical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Holstebro, , Denmark
Patients applied
Trial Officials
Erling B Pedersen, Prof, MSci
Principal Investigator
Department of Medical Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials